Ricinus communis L. (family Euphorbiaceae), known in Ayurveda as Eranda and commonly as the castor oil plant, must be discussed by plant part. The Ayurvedic Pharmacopoeia of India (API) monographs its dried mature root, while the European Medicines Agency (EMA) monographs seed oil obtained by cold expression for short-term treatment of occasional constipation. Modern evidence clearly explains the oil’s laxative action; evidence for anti-inflammatory, analgesic, hair, scalp, and wound applications is substantially more limited.

Botanical Profile and Fatty Acid Composition

The API describes Ricinus communis as a tall glabrous shrub or almost small tree, about 2–4 m high, found throughout India, growing wild on wasteland and cultivated for its oil seeds. Its Eranda monograph applies specifically to the root. The EMA assessment describes castor oil as a triglyceride mixture rich in ricinolein, the glyceride of ricinoleic acid.

European Pharmacopoeia specifications cited by the EMA give the following ranges for the fatty-acid fraction of virgin and refined castor oil:

  • Ricinoleic acid: 85–92%.
  • Oleic acid and isomers: 2.5–6.0%.
  • Linoleic acid: 2.5–7.0%.
  • Palmitic acid: not more than 2%; stearic acid: not more than 2.5%.
  • Linolenic acid, eicosenoic acid, and any other individual fatty acid: not more than 1% each.

Castor beans contain ricin, a highly toxic protein that inhibits cellular protein synthesis. The EMA assessment states that ricin remains in the bean pulp after oil isolation and that castor oil is not considered to contain ricin. Raw beans nevertheless remain dangerous and must never be chewed or swallowed; oral use should involve a properly manufactured medicinal oil, not homemade seed preparations.

Ayurvedic Identity, Properties, and Uses

The API entry “Eranda (Root)” records madhura rasa, guru and snigdha guna, ushna virya, madhura vipaka, and the actions vatahara, vrishya, and amapachana. These official root attributes should not automatically be transferred to every seed-oil product or topical cosmetic preparation.

The monograph lists shotha, jvara, udararoga, amavata, vasti-shula, and kati-shula among therapeutic uses. It names Gandharvahastadi Kvatha Curna, Vatari Guggulu, and Gandharvahasta Taila as important formulations. The stated dose is 20–30 g of root for decoction; this is not a castor-oil dose and requires interpretation by a qualified Ayurvedic practitioner.

Laxative Mechanism: Ricinoleic Acid and EP3

After oral administration, pancreatic enzymes hydrolyse castor oil and release ricinoleic acid. A 2012 study in Proceedings of the National Academy of Sciences (PMID 22615395) showed that ricinoleic acid activates prostaglandin E receptor subtype EP3. Mice lacking EP3 did not show the usual laxative or uterine-contracting responses.

Deleting EP3 from intestinal epithelial cells did not abolish castor-oil-induced diarrhoea, whereas deleting it from smooth-muscle cells removed the response. The best-supported receptor mechanism is therefore EP3-mediated intestinal smooth-muscle contraction and motility, not an EP3 pathway chiefly producing chloride secretion or villus contraction. The EMA additionally states that ricinoleic acid reduces net fluid and electrolyte absorption and stimulates intestinal peristalsis.

The final EMA monograph classifies castor oil as a contact laxative for short-term occasional constipation. For adults and older people it gives 2–5 g, equivalent to 2.1–5.3 mL, as a single dose, usually no more than two or three times weekly; onset varies from two to six hours. Product instructions and national regulations can differ, so the local label and professional advice take precedence.

Anti-inflammatory and Analgesic Evidence

Ricinoleic acid has shown anti-inflammatory and antinociceptive activity in experimental animals. A 2000 study (PMID 11200362) reported reductions in established oedema in animal inflammation models after repeated treatment. Another study (PMID 11050297) found antinociceptive effects after repeated local treatment and decreased substance P levels in mouse paw tissue.

Animal findings should not be converted into unsupervised treatment recommendations or represented as proof of clinical efficacy.

The main clinical osteoarthritis report was an oral active-comparator study. One hundred participants with knee osteoarthritis received either a 0.9 mL castor-oil capsule three times daily or diclofenac 50 mg three times daily for four weeks (PMID 19288533). Both groups improved, but there was no placebo group, and the study does not establish that topical castor-oil packs penetrate joints or provide comparable benefit.

Hair, Scalp, Skin, and Wound Claims

Castor oil is widely used as a cosmetic oil, but cosmetic use is not proof of treatment efficacy. A 2022 systematic review found weaker evidence for improving hair luster or quality and no strong evidence that castor oil promotes hair growth. No reliable controlled clinical trial was located for reducing scalp Malassezia or dandruff compared with mineral oil.

Castor oil should not be applied to an open or infected wound unless it is part of a clinician-selected regulated product. Allergic contact dermatitis to castor oil or ricinoleic acid has been documented.

Applications and Dosage Summary

Evidence and dosing depend on the exact material—root, regulated seed oil, isolated ricinoleic acid, or cosmetic oil. This summary separates official guidance from preliminary or unsupported applications and is not an individualized prescription.

Application Material / Route Verified Dose or Method Evidence Status
Occasional constipation Medicinal castor oil, oral EMA: 2.1–5.3 mL as one adult dose; usually up to 2–3 times weekly Well-established short-term use
Eranda root decoction Dried mature root API: 20–30 g for decoction Official Ayurvedic guidance
Knee osteoarthritis Castor-oil capsule, oral 0.9 mL three times daily for four weeks in one trial Preliminary; not standard care
Joint packs or massage Topical oil No validated clinical schedule Traditional use; efficacy unestablished
Hair, dandruff, or wounds Topical oil No verified therapeutic regimen Cosmetic or unsupported clinical use

Ricinoleic Acid Mechanism Infographic

Digestion releases ricinoleic acid, EP3 activation in intestinal smooth muscle promotes contraction, and net intestinal fluid and electrolyte absorption is reduced. Anti-inflammatory and cosmetic claims should not be presented as equally proven mechanisms.

ERANDA SEED OIL: VERIFIED ORAL LAXATIVE PATHWAY
1. HYDROLYSIS
Pancreatic enzymes release ricinoleic acid from castor-oil triglycerides.

2. EP3 ACTIVATION
Ricinoleic acid activates EP3 receptors on intestinal smooth muscle.

3. LAXATION
Contraction, peristalsis, and reduced net absorption promote evacuation.

Safety Profile: Distinguishing Oil from Seed

Medicinal castor oil is intended for short-term occasional constipation. The EMA lists nausea, vomiting, abdominal pain, and severe diarrhoea as possible adverse effects; overdose can cause colic, dehydration, and electrolyte loss. Long-term laxative use should be avoided, and constipation requiring daily treatment should be investigated.

The EMA contraindicates castor oil in intestinal obstruction or stenosis, intestinal atony, appendicitis, inflammatory colon disease, unexplained abdominal pain, severe dehydration, pregnancy, and lactation. Its monograph does not recommend oral use below age 18 because adequate safety and efficacy data are lacking. Castor oil should never be used for self-induction of labour.

Low potassium caused by prolonged laxative misuse can increase the effects of cardiac glycosides and interact with antiarrhythmics; diuretics, corticosteroids, and liquorice root may further increase potassium loss. Anyone considering oral castor oil or Eranda therapy—especially a child, a pregnant or breastfeeding person, or someone with persistent constipation, bowel disease, abdominal pain, or regular medicines—should consult a qualified Ayurvedic practitioner and an appropriate healthcare provider.

Conclusion

Eranda is an authentic Ayurvedic drug, but its root, seed oil, raw seed, and finished formulations are not interchangeable. The API verifies the root’s identity, properties, actions, uses, formulations, and decoction dose. Modern evidence most strongly supports properly manufactured castor oil as a short-term laxative whose released ricinoleic acid activates EP3 receptors in intestinal smooth muscle. Anti-inflammatory and analgesic findings are mainly preclinical, the osteoarthritis evidence is limited to one oral comparator trial, and claims for topical packs, dandruff, hair growth, or wound healing remain unestablished. Never ingest raw castor beans, and use medicinal Eranda preparations only with appropriate professional guidance.

References

  1. Ayurvedic Pharmacopoeia of India
  2. Ayurvedic Pharmacopoeia of India
  3. Ema (ema.europa.eu)
  4. Ema (ema.europa.eu)
  5. CDC
  6. Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors (2012), PubMed
  7. Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors (2012), PubMed Central
  8. Effect of ricinoleic acid in acute and subchronic experimental models of inflammation (2000), PubMed
  9. Antinociceptive activity of ricinoleic acid, a capsaicin-like compound devoid of pungent properties (2000), PubMed
  10. Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis (2009), PubMed
  11. Coconut, Castor, and Argan Oil for Hair in Skin of Color Patients: A Systematic Review (2022), PubMed
  12. Allergic contact dermatitis from 12-hydroxystearic Acid and hydrogenated castor oil (2009), PubMed
  13. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha (2002), PubMed
  14. Supersonic gas chromatography/mass spectrometry (2001), PubMed
  15. CRF and CRF receptors (1999), PubMed
  16. Systemic lupus erythematosus and vaccination (2009), PubMed